
TY  - JOUR
TI  - Poster Presentations
JO  - Journal of Gastroenterology and Hepatology
JA  - J Gastroenterol Hepatol
VL  - 28
IS  - S3
SN  - 0815-9319
UR  - https://doi.org/10.1111/jgh.12363_2
DO  - doi:10.1111/jgh.12363_2
SP  - 23
EP  - 693
PY  - 2013
ER  - 

AU  - Crookston, Kendall P.
AU  - Wilkinson, Susan L.
AU  - Simon, Toby L.
C7  - pp. 973-992
TI  - Recruitment and Screening of Donors and the Collection, Processing, and Testing of Blood
SN  - 9781405175883
UR  - https://doi.org/10.1002/9781444303513.ch62
DO  - doi:10.1002/9781444303513.ch62
SP  - 973-992
KW  - recruitment and screening of donors
KW  - recruitment of blood donors
KW  - donor motivation
KW  - deterrents to donation
KW  - collection process for blood components for transfusion
KW  - leukocyte reduction
KW  - ABO/Rh testing
KW  - blood donor adverse events
KW  - long-term effects of donation
PY  - 2013
AB  - Summary This chapter contains sections titled: Organization of Blood Services Recruitment of Blood Donors The Collection Process for Blood Components for Transfusion The Collection Process for Source Plasma Blood Donor Adverse Events Conclusion Disclaimer References
ER  - 

AU  - Gandhi, Nilay M.
AU  - Bertrand, Laura A.
AU  - Lamm, Donald L.
AU  - O'Donnell, Michael A.
C7  - pp. 76-88
TI  - Intravesical immunotherapy
SN  - 9781118674840
UR  - https://doi.org/10.1002/9781118674826.ch7
DO  - doi:10.1002/9781118674826.ch7
SP  - 76-88
KW  - bacillus Calmette-Guérin (BCG)
KW  - non-muscle-invasive bladder cancer (NMIBC)
KW  - superficial bladder cancer
KW  - high-grade bladder cancer
KW  - intravesical immunotherapy
KW  - BCG maintenance
KW  - Interferon-α
KW  - BCG toxicity
PY  - 2013
AB  - Summary This chapter describes the emergence of bacillus Calmette-Guérin (BCG) immunotherapy as a treatment for high-grade, non-muscle-invasive bladder cancer. Comparisons with various intravesical chemotherapeutic regimens have consistently demonstrated BCG complete response rates of 55?65% for papillary Ta or T1 tumors and 70?75% for carcinoma in situ (CIS). The innate immune system is utilized by BCG, specifically the T-helper (Th)-1 cytokine pathway. The results of large, randomized trials have confirmed the importance of three-week BCG maintenance in intermediate- and high-risk patients and suggest that the use of BCG may improve both cancer-specific survival and progression-free survival. Patients may be refractory or resistant to treatment, or experience intolerance due to side effects; therefore, newer treatments involving other cytokines are being developed and utilized.
ER  - 

TY  - JOUR
TI  - E-Poster Presentations (Oral) | APDW 2019
JO  - Journal of Gastroenterology and Hepatology
JA  - Journal of Gastroenterology and Hepatology
VL  - 34
IS  - S3
SN  - 9781118674840
UR  - https://doi.org/10.1111/jgh.14879
DO  - doi:10.1111/jgh.14879
SP  - 72
EP  - 582
PY  - 2019
ER  - 

TY  - JOUR
TI  - Research Abstract Program of the 21st Annual ACVIM Forum Charlotte, NC, June 4–7, 2003
JO  - Journal of Veterinary Internal Medicine
VL  - 17
IS  - 3
SN  - 9781118674840
UR  - https://doi.org/10.1111/j.1939-1676.2003.tb02465.x
DO  - doi:10.1111/j.1939-1676.2003.tb02465.x
SP  - 369
EP  - 460
PY  - 2003
ER  - 

TY  - JOUR
AU  - Hughes, Phillip F.
AU  - Carmichael, Eleanor M.
AU  - Cull, Anthony B.
TI  - Toxic Shock Syndrome Presenting to a Paediatric Service
JO  - Australian and New Zealand Journal of Obstetrics and Gynaecology
VL  - 25
IS  - 4
SN  - 9781118674840
UR  - https://doi.org/10.1111/j.1479-828X.1985.tb00749.x
DO  - doi:10.1111/j.1479-828X.1985.tb00749.x
SP  - 292
EP  - 295
PY  - 1985
AB  - Summary: A case of toxic shock syndrome occuring in a 13-year-old and presenting to a paediatric service is described. Some implications are discussed including an approach to menstrual protection and the question of future contraceptive needs.
ER  - 

TY  - JOUR
TI  - Print-only Abstracts*
JO  - Vox Sanguinis
VL  - 87
IS  - s3
SN  - 9781118674840
UR  - https://doi.org/10.1111/j.1423-0410.2004.00519.x
DO  - doi:10.1111/j.1423-0410.2004.00519.x
SP  - 93
EP  - 145
PY  - 2004
ER  - 

TY  - JOUR
TI  - Annual Meeting of the American Epilepsy Society
JO  - Epilepsia
VL  - 45
IS  - s7
SN  - 9781118674840
UR  - https://doi.org/10.1111/j.0013-9580.2004.t01-21-00001.x
DO  - doi:10.1111/j.0013-9580.2004.t01-21-00001.x
SP  - 1
EP  - 368
PY  - 2004
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Transfusion Medicine
JA  - Transfusion Med
VL  - 24
IS  - s1
SN  - 9781118674840
UR  - https://doi.org/10.1111/tme.12112
DO  - doi:10.1111/tme.12112
SP  - 15
EP  - 48
PY  - 2014
ER  - 

TY  - JOUR
TI  - Tuesday, 26 July 2011
JO  - Journal of Thrombosis and Haemostasis
VL  - 9
IS  - s2
SN  - 9781118674840
UR  - https://doi.org/10.1111/j.1538-7836.2011.04380_2.x
DO  - doi:10.1111/j.1538-7836.2011.04380_2.x
SP  - 251
EP  - 498
PY  - 2011
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - International Journal of Rheumatic Diseases
JA  - Int J Rheum Dis
VL  - 17
IS  - s1
SN  - 9781118674840
UR  - https://doi.org/10.1111/1756-185x.12344
DO  - doi:10.1111/1756-185x.12344
SP  - 1
EP  - 133
PY  - 2014
ER  - 

TY  - JOUR
TI  - POSTER ABSTRACTS
JO  - Alcoholism: Clinical and Experimental Research
VL  - 28
IS  - s3
SN  - 9781118674840
UR  - https://doi.org/10.1111/j.1530-0277.2004.tb03608.x
DO  - doi:10.1111/j.1530-0277.2004.tb03608.x
SP  - 7A
EP  - 52A
PY  - 2004
ER  - 

TY  - JOUR
TI  - Posters
JO  - Journal of the European Academy of Dermatology and Venereology
VL  - 18
IS  - s2
SN  - 9781118674840
UR  - https://doi.org/10.1111/j.1468-3083.2004.01152.x
DO  - doi:10.1111/j.1468-3083.2004.01152.x
SP  - 193
EP  - 557
PY  - 2004
ER  - 

TY  - JOUR
TI  - ACR Meeting
JO  - Arthritis & Rheumatism
JA  - Arthritis & Rheumatism
VL  - 64
IS  - S10
SN  - 9781118674840
UR  - https://doi.org/10.1002/art.37735
DO  - doi:10.1002/art.37735
SP  - S1
EP  - S1216
PY  - 2012
AB  - Abstract http://acrmeeting.wiley.com/
ER  - 

TY  - JOUR
AU  - Schwartz, Joseph
AU  - Padmanabhan, Anand
AU  - Aqui, Nicole
AU  - Balogun, Rasheed A.
AU  - Connelly-Smith, Laura
AU  - Delaney, Meghan
AU  - Dunbar, Nancy M.
AU  - Witt, Volker
AU  - Wu, Yanyun
AU  - Shaz, Beth H.
TI  - Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue
JO  - Journal of Clinical Apheresis
JA  - J. Clin. Apheresis
VL  - 31
IS  - 3
SN  - 9781118674840
UR  - https://doi.org/10.1002/jca.21470
DO  - doi:10.1002/jca.21470
SP  - 149
EP  - 338
KW  - apheresis
KW  - plasma exchange
KW  - immunoadsorption
KW  - leukocytapheresis
KW  - photopheresis
KW  - indications evidence based
KW  - adsorptive cytapheresis
KW  - therapeutic plasma exchange
KW  - erythrocytapheresis
KW  - red blood cell exchange
KW  - thrombocytapheresis
KW  - platelet pheresis
KW  - leukocytapheresis
KW  - filtration-based selective apheresis
KW  - extracorporeal photopheresis
KW  - immunoadsorption
KW  - LDL apheresis
KW  - adsorptive cytapheresis
KW  - B2 microglobulin column
KW  - highvolume plasma exchange
KW  - rheopheresis
PY  - 2016
AB  - The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special Issue Writing Committee is charged with reviewing, updating, and categorizing indications for the evidence-based use of therapeutic apheresis in human disease. Since the 2007 JCA Special Issue (Fourth Edition), the Committee has incorporated systematic review and evidence-based approaches in the grading and categorization of apheresis indications. This Seventh Edition of the JCA Special Issue continues to maintain this methodology and rigor to make recommendations on the use of apheresis in a wide variety of diseases/conditions. The JCA Seventh Edition, like its predecessor, has consistently applied the category and grading system definitions in the fact sheets. The general layout and concept of a fact sheet that was used since the fourth edition has largely been maintained in this edition. Each fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis in a specific disease entity. The Seventh Edition discusses 87 fact sheets (14 new fact sheets since the Sixth Edition) for therapeutic apheresis diseases and medical conditions, with 179 indications, which are separately graded and categorized within the listed fact sheets. Several diseases that are Category IV which have been described in detail in previous editions and do not have significant new evidence since the last publication are summarized in a separate table. The Seventh Edition of the JCA Special Issue serves as a key resource that guides the utilization of therapeutic apheresis in the treatment of human disease. J. Clin. Apheresis 31:149?162, 2016. ? 2016 Wiley Periodicals, Inc.
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - European Journal of Heart Failure
JA  - Eur J Heart Fail
VL  - 16
IS  - s1
SN  - 9781118674840
UR  - https://doi.org/10.1002/ejhf.77
DO  - doi:10.1002/ejhf.77
SP  - 1
EP  - 41
PY  - 2014
ER  - 

TY  - JOUR
TI  - Free Communications
JO  - British Journal of Haematology
VL  - 129
IS  - s1
SN  - 9781118674840
UR  - https://doi.org/10.1111/j.1365-2141.2005.05435.x
DO  - doi:10.1111/j.1365-2141.2005.05435.x
SP  - 1
EP  - 83
PY  - 2005
ER  - 

TY  - JOUR
TI  - ABSTRACTS FOR THE 10TH WORLD CONGRESS ON PEDIATRIC DERMATOLOGY
JO  - Pediatric Dermatology
VL  - 21
IS  - 3
SN  - 9781118674840
UR  - https://doi.org/10.1111/j.0736-8046.2004.21332.x
DO  - doi:10.1111/j.0736-8046.2004.21332.x
SP  - 312
EP  - 425
PY  - 2004
ER  - 

TY  - JOUR
TI  - Abstracts cont.
JO  - Clinical Microbiology and Infection
VL  - 11
IS  - s2
SN  - 9781118674840
UR  - https://doi.org/10.1111/j.1469-0691.2005.clm_1134_01.x
DO  - doi:10.1111/j.1469-0691.2005.clm_1134_01.x
SP  - 99
EP  - 237
PY  - 2005
ER  - 

AU  - Abdel-Razeq, Sonya S.
AU  - Norwitz, Errol R.
C7  - pp. 599-629
TI  - Septic Shock
UR  - https://doi.org/10.1002/9781119129400.ch38
DO  - doi:10.1002/9781119129400.ch38
SP  - 599-629
KW  - ARDS
KW  - clinical syndrome
KW  - pregnancy
KW  - septic shock
KW  - SIRS
PY  - 2005
AB  - Summary Septic shock is characterized by an inability of the host to maintain vascular integrity and fluid homeostasis, resulting in inadequate tissue oxygenation and circulatory failure. The systemic inflammatory response syndrome (SIRS) describes a generalized inflammatory response of the host to a variety of insults. SIRS is considered a clinical syndrome that is a form of dysregulated inflammation. Disruption of the endothelium and vascular smooth muscle is a well-recognized component of septic shock. The clinical spectrum of sepsis depends primarily on the host response to infection rather than the severity of the infection itself. The pregnant host may be different from the traditional septic shock host in ways other than the difference in microbiologic pathogens involved. Physiologic adaptations to pregnancy designed to promote favorable maternal and fetal outcome occur in almost every organ system. Acute respiratory distress syndrome (ARDS) develops in 50 percent of patients with severe sepsis or septic shock.
ER  - 
